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Mast Cells in Bacterial Infections 
Abstract 
Mast cells are implicated in immunity towards bacterial infection, but the molecular 
mechanisms by which mast cells contribute to the host response are only partially 
understood. Previous studies have examined how mast cells react to purified bacterial 
cell wall components, such as peptidoglycan and lipopolysaccharide. To investigate 
how mast cells react to live bacteria we co-cultured mast cells and the gram-positive 
bacteria Streptococcus equi (S. equi) and Staphylococcus aureus (S. aureus). Gene 
array analysis showed that mast cells upregulate a number of genes in response to live 
bacteria. Many of these corresponded to pro-inflammatory cytokines, but also 
numerous additional genes, including transcription factors, signaling molecules and 
proteases were upregulated. The release of cytokines was confirmed on the protein 
level by antibody-based cytokine/chemokine arrays and/or ELISA. 
Granzyme D, a protease mainly expressed in cytotoxic T cells, was one of the genes 
that were upregulated by S. equi. We showed that granzyme D is expressed by murine 
mast cells and that its level of expression correlated positively with the extent of mast 
cell maturation. Granzyme D expression was also induced by stem cell factor, IgE 
receptor cross-linking and calcium ionophore stimulation. 
Previous studies investigating the role of mast cells in bacterial infection in vivo have 
used mice that are mast cell deficient due to mutations in Kit-signaling. However, these 
mutations also influence other cell types than mast cells. Thus, to study the role of mast 
cells during in vivo infection with S. aureus we used the newly developed Mcpt5-Cre+ x 
R-DTA mice whose expression of diphteria toxin under the Mcpt5 promoter selectively 
depletes mast cells. S. aureus was injected intraperitoneally into Mcpt5-Cre+ x R-DTA 
mice using littermate mast cell-sufficient mice as controls. We did not observe any 
difference between mast cell-deficient and control mice in regard to weight loss, 
bacterial clearance, inflammation or cytokine production. We conclude that, despite 
mast cells being activated by S. aureus in vitro, mast cells do not influence the in vivo 
manifestations of S. aureus intraperitoneal infection. However, to make more general 
conclusions about the role of mast cells in bacterial infections, more studies in the new 
mast cell-deficient mice are needed using other bacterial strains and other routes of 
administration. 
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1 Abbreviations 
ADAMTS A disintegrin and metalloproteinase with thrombospondin motif 
bFGF basic fibroblast growth factor  
BMMC Bone-Marrow derived Mast Cells 
CCL C-C motif ligand 
CPA Carboxypeptidase A 
CLP Caecal ligation and puncture 
CR Complement receptor 
CRAMP Cathelicidin- related antimicrobial peptide 
CTMC Connective tissue mast cell 
CXCL C-X-C motif ligand 
DT Diphtheria toxin 
DTR Diphtheria toxin receptor 
ECM Extracellular matrix 
ELISA Enzyme-linked immunosorbent assay 
GAG Glycosaminoglycan 
GM-CSF granulocyte-macrophage colony-stimulating factor  
i.d. intradermally 
i.p. intraperitoneally 
i.v. intravenously 
ICAM Intracellular adhesion molecule 
IE Intronic enhancer 
Ig Immunoglobin 
IL Interleukin 
LFA Leukocyte function associated antigen 
LIF Leukemia inhibitory factor 
LPS Lipopolysaccaride 
LT Leukotiene 
Mcl-1 Myeloid cell leukemia sequence 1 
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MCP Monocyte chemoattractant protein 
MCT Human mast cells that contain tryptase 
MCTC Human mast cells that contain tryptase and chymase 
MIP Macrophage inflammatory protein 
MMC  Mucosal mast cell 
mMCP Mouse mast cell protease 
MMP Matrix metalloprotease 
mTMT Mouse transmembrane tryptase 
NF-κβ Nuclear factor-κβ 
NFAT Nuclear factor of activated T-cells 
NOD Nucleotide-binding oligomerization domain 
PAMP Pathogen-associated molecular pattern 
PAR Protease activated receptor 
PCMC Peritoneal cell derived mast cell 
PGD2 Prostaglandin D2 
PGE2 Prostaglandin E2 
PG Proteoglycan 
PGN Peptidoglycan 
PKC Protein kinase C 
SCF Stem cell factor 
TCR T cell receptor 
TGF Transforming growth factor 
TH T helper 
TLR Toll-Like Receptor 
TNF Tumor necrosis factor 
   
 10 
2 Introduction 
2.1 The immune system 
In our everyday life we encounter many different pathogens (bacteria, viruses, 
fungi and parasites). It is the immune system’s job to protect us from these 
pathogens. The immune system is divided into two components: the innate and 
the adaptive immune response. The innate immune system is often referred to 
as the first line of defense, which enables us to protect ourselves even on the 
first encounter with the pathogen. It includes anatomic barriers such as the 
skin, tears, saliva and mucosal surfaces as well as the complement system and 
various cells including mast cells, eosinophils, basophils and phagocytes 
(macrophages, neutrophils and dendritic cells). The adaptive immune system is 
specific toward one particular pathogen or antigen, which develops as a 
consequence of exposure to that particular pathogen. The leukocytes of the 
adaptive immune system are divided into B cells and T cells. The B cells 
participate in antibody-mediated responses and T cells in cell-mediated 
immune responses. Even though the innate and adaptive responses are often 
regarded as two separate components, cross-talk between them through 
cytokine secretion and cell to cell signaling is essential for a proper immune 
response (Crozat et al., 2009).  
2.2 Mast cells 
Mast cells are highly granulated cells found throughout all vascularized tissues, 
often close to blood vessels. They are common at host-environment interfaces 
such as the skin and mucosal tissues. Because of their location, as well as being 
equipped with innate receptors that can react directly upon invading pathogens, 
they are known as a “first line of defense” cell. The mast cell granules are 
filled with mediators that can be released immediately upon activation. In 
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addition, mast cells can also produce new (“de novo”) mediators upon 
activation (Metcalfe et al., 1997).  
Mast cells derive from pluripotent hematopoietic stem cells in the bone 
marrow. However, they do not go through their final stages of maturation until 
the precursors have entered the tissues (Kirshenbaum et al., 1991). Mast cells 
are long-lived cells, which can regranulate after having degranulated (Xiang et 
al., 2001).  
2.3 Heterogeneity of mast cells 
In rodents, mast cells are divided into connective tissue type mast cells 
(CTMCs) and mucosal mast cells (MMCs). As indicated by their names, they 
are located at different anatomical sites, but they also differ in their mast cell 
protease and proteoglycan (PG) content (Enerback, 1966) (Table 1). In 
humans, mast cells are classified depending on their mast cell protease content 
and are divided into MCT, containing tryptase, and MCTC, containing both 
tryptase and chymase (Irani & Schwartz, 1994) (Table 1). 
Table 1. Summary of the mast cell specific protease and proteoglycan content in humans and 
mice. 
Species Human  Mouse  
MC-subclass MCT MCTC CTMC MMC 
Chymase - + mMCP-4 
mMCP-5 
mMCP-1 
mMCP-2 
Tryptase α-tryptase 
β-tryptase 
α-tryptase 
β-tryptase 
mMCP-6 
mMCP-7 
- 
CPA - + + - 
Proteoglycan Heparin/ 
chondroitin 
sulfate 
Heparin/ 
chondroitin 
sulfate 
Heparin Chondroitin 
sulfate 
 
2.4 Mast cell activation 
Mast cells can rapidly respond to various stimuli by degranulating but they can 
also be activated to produce de novo mediators. Activation may occur by 
various mechanisms, including cross-linking of surface-associated 
immunoglobulin (Ig)E or IgG receptors, exposure to bacterial components and 
complement factors. This is described below. 
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2.4.1 IgE-dependent activation 
The most studied way of mast cell activation, especially in the context of 
allergic reactions, is cross-linking of their high-affinity IgE receptors, FcεRI. 
When an antigen enters the body it may provoke production of IgE antibodies. 
The IgE antibodies bind tightly to the FcεRI on the mast cells and exposure to 
the antigen a second time will cross-link FcεRI on the mast cell surface.  
Cross-linking of the receptors leads to intracellular signaling events and 
consequent degranulation, as well as de novo synthesis of various mediators 
(Turner & Kinet, 1999). Mast cell FcεRI is a tetrameric protein complex 
(Blank et al., 1989; Ra et al., 1989), consisting of an IgE-binding α-subunit 
(Hakimi et al., 1990), a signal-amplifying membrane-spanning β-subunit as 
well as a homodimeric disulphide-linked γ-subunit (Perez-Montfort et al., 
1983), which gives the receptor the ability to signal. (Jouvin et al., 1994).  
2.4.2 IgG-mediated activation 
Mast cell activation can also be achieved via receptors for IgG (FcγRs). Human 
mast cells express the high-affinity receptor, FcγRI, and the low-affinity 
receptor, FcγRII. In contrast, murine mast cells express the low-affinity 
receptors, FcγRII and FcγRIII (Okayama et al., 2000; Katz & Lobell, 1995). 
Mast cell degranulation can be triggered by stimulation of FcγRI and FcγRIII 
(Daeron et al., 1995). However, cross-linking of FcγRII results in decreased 
signaling from activated IgE- and IgG-receptors, thereby inhibiting mast cell 
degranulation (Kepley et al., 2000; Daeron & Vivier, 1999). 
The Fc receptors bind to pathogen-specific antibodies that aid mast cells in 
pathogen recognition and elicitation of a proper immune response. 
2.4.3 Toll-like receptors 
Mast cells can recognize and be activated by pathogens through their toll-like 
receptors (TLRs). TLRs are activated by specific molecules from the 
pathogens, termed pathogen-associated molecular patterns (PAMPs). TLR-2, -
3, -4, -6, -8 and -9 are expressed on mast cells (Matsushima et al., 2004; 
Takeda et al., 2003; Supajatura et al., 2001). Different PAMPs stimulate 
different TLRs. For example, lipopolysaccaride (LPS), a gram-negative 
bacterial cell wall component, activates TLR-4 and viral dsRNA activates 
TLR-3. TLRs may also facilitate cooperative binding of ligands, and thereby 
exhibit a broad recognition spectrum. For example, TLR-2/6 recognizes 
peptidoglycan (PGN), a component of the gram-positive bacterial cell wall, 
whereas TLR-1/2, recognizes triacylated lipoproteins (Takeda et al., 2003). 
Activation of mast cells via their TLRs is usually associated with cytokine, 
leukotriene and prostaglandin production without causing degranulation 
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(Marshall et al., 2003). However, activation of TLR-2 has been shown to cause 
degranulation as well (Supajatura et al., 2002). Mast cells may thus recruit 
other immune cells to the site of infection by responding to various bacterial, 
viral and fungal components through TLR signaling pathways. 
2.4.4 Complement-mediated activation 
The complement system is composed of serum proteins and cell surface 
receptors, which interact in a number of complex pathways and can be 
activated by invading pathogens or tissue damage. The complement system is 
associated with both the innate and adaptive immune responses (Sarma & 
Ward, 2011). Mast cells express complement receptor (CR)3, CR4, C3aR and 
C5aR (Marshall, 2004). In mice, only CTMCs, but not MMCs, express CRs, 
which are able to respond to C3a and C5a (Mousli et al., 1994). Complement 
deficient mice are more sensitive to cecal ligation and puncture (CLP), a model 
for bacterial sepsis, and display reduced mast cell activation (Prodeus et al., 
1997). Human mast cells display varying expression levels of CRs depending 
on the surrounding milieu. Skin and cardiac mast cells express C5aR but mast 
cells from the lungs, uterus or tonsils do not (Fureder et al., 1995). In addition 
to their function as mast cell activating agents, C3a and C5a have been shown 
to be chemotactic for mast cells (Nilsson et al., 1996). 
2.4.5 Other mechanisms of activation 
In addition to the previously mentioned modes of mast cell activation, there are 
a number of other ways they can be activated, including activation by 
cytokines/chemokines, neuropeptides, calcium ionophores and drugs.  
Many different cytokines can influence and activate mast cells, including 
interleukin (IL)-1, IL-3, IL-8, granulocyte-macrophage colony stimulating 
factor, macrophage inflammatory protein (MIP)-1, monocyte chemoattractant 
protein (MCP)-1 and stem cell factor (SCF) (Mekori & Metcalfe, 2000; Taylor 
et al., 1995; Alam et al., 1994; Subramanian & Bray, 1987). In addition, 
production of various cytokines can be induced by the lipid mediators 
prostaglandin E2 (PGE2) and leukotriene (LT)C4 (Abdel-Majid & Marshall, 
2004; Mellor et al., 2002; Leal-Berumen et al., 1995). 
Mast cells are often situated close to nerve endings and can also be 
activated by neuropeptides such as substance P, calcitonin gene-related 
peptide, vasoactive intestinal peptide and neurotensin. Other small peptides, 
such as endothelin-1, expressed by endothelial cells, also activate mast cells 
(Bauer & Razin, 2000; Metcalfe et al., 1997). 
Mast cell degranulation can be mediated by elevating intracellular calcium 
levels. Therefore calcium mobilizing agents, such as calcium ionophores, 
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A23187 and ionomycin, have the ability to cause mast cell degranulation. 
Basic compounds, for example compound 48/80, can also directly activate 
mast cells and cause degranulation (Metcalfe et al., 1997). 
Furthermore, cell-cell contact can also cause mast cell activation. 
Interaction of mast cells with activated T cells via leukocyte function 
associated antigen (LFA)-1 and intracellular adhesion molecule (ICAM)-1, 
induces cytokine production and mediator release (Bhattacharyya et al., 1998; 
Inamura et al., 1998). 
In addition to the TLRs, mast cells can also react to pathogens through 
CD48 that recognizes the FimH protein, which can be expressed, for example, 
by Escherichia coli (E. coli) (Malaviya et al., 1999), as well as nucleotide-
binding oligomerization domain (NOD) receptors, which are intracellular 
sensors of PAMPs (Enoksson et al., 2011; Wu et al., 2007). Other mast cell 
activators include the nucleoside adenosine and the opiates morphine and 
codine (Mekori & Metcalfe, 2000). 
Individual stimuli of mast cells can elicit distinct, but sometimes 
overlapping patterns of mediator release. For example, IgE-mediated activation 
leads to degranulation, de novo synthesis and release of mediators, whereas 
LPS via stimulation of TLR-4, induces release of certain cytokines without 
degranulation. 
 
 
2.5 Mast cell mediators 
Mast cells have the potential to produce and release many mediators. Some of 
these are preformed and stored in granules; these include neutral proteases, 
PGs, biogenic amines and some cytokines. Other mediators, including lipid 
mediators and cytokines, are only synthesized and released after the mast cell 
has been activated. 
2.5.1 Mast cell proteases 
The granules of mast cells contain large amounts of proteases; up to 35% of the 
total protein content. The mast cell specific proteases include tryptases, 
chymases and carboxypeptidase A3 (CPA3), but mast cells also express other 
proteases including lysosomal cathepsins, granzymes, matrix metalloproteases 
(MMPs), and A disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTSs) (Garcia-Faroldi et al., 2013; Pejler et al., 2010; Pejler et al., 
2007).  
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Tryptase 
Tryptases are serine proteases with trypsin-like cleavage specificity, i.e., they 
cleave after lysine/arginine residues, which are active in a tetrameric form with 
the active sites facing the central pore. The tetrameric structure of tryptase 
provides its selective substrate specificity, as it can only cleave relatively small 
substrates that can enter the central pore. The structure also protects tryptase 
against macromolecular inhibitors that cannot enter the pore. Tryptase is stored 
in an active form in complex with serglycin PG within the mast cell granules 
(Pejler et al., 2007; Hallgren et al., 2001; Schwartz & Bradford, 1986). 
Humans mainly express two types of tryptases: α-tryptases and β-tryptases. β-
tryptases are further classified into βI-, βII- and βII-tryptases and the α-
tryptases into αI- and αII-tryptases (Pallaoro et al., 1999). β-tryptases are the 
main form found in mast cells and are the most catalytically active (Marquardt 
et al., 2002; Huang et al., 1999). α-tryptases can be found in the circulation in 
the absence of mast cell degranulation, which suggests that they are 
constitutively secreted (Schwartz et al., 1995). In addition to the α- and β-
tryptases, human tryptases also include δ-tryptase and the membrane anchored 
γ-tryptase (Hallgren & Pejler, 2006). 
Mice have been found to express four tryptases: mouse mast cell protease 
(mMCP)-6, mMCP-7, mMCP-11 and mouse transmembrane tryptase (mTMT). 
mMCP-6 is the most similar to human β-tryptase, both in sequence homology 
and cleavage specificity (Pejler et al., 2007). mMCP-11 and mTMT have both 
been found to be mainly expressed in the early stages of mast cell development 
(Wong et al., 2004; Wong et al., 1999).  
Tryptase has been suggested to degrade a number of extracellular matrix 
(ECM) components, such as fibrinogen (Schwartz et al., 1985), fibronectin 
(Lohi et al., 1992), type VI collagen (Kielty et al., 1993) and to activate pro-
MMP-3 (Gruber et al., 1989). Additionally, tryptase has been shown to cleave 
and thereby activate protease-activated receptor (PAR)-2, which may lead to 
inflammatory events, such as recruitment of eosinophils (Matos et al., 2013; 
Berger et al., 2001). Tryptase can also recruit neutrophils (Huang et al., 1998) 
and a study in mMCP-6 knockout mice has also shown that mMCP-6 
contributes to the defense against intraperitoneal Klebsiella pneumoniae (K. 
pneumoniae) infection by influencing early neutrophil recruitment (Thakurdas 
et al., 2007). In addition to a role in bacterial infections, studies of mMCP-6 
knockout mice have shown that mMCP-6 is involved in eosinophil recruitment 
to skeletal muscle infected by the parasite Trichinella spiralis (Shin et al., 
2008) and that mMCP-6 has a harmful role in arthritis (McNeil et al., 2008). 
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Chymase 
Chymases are serine proteases with chymotrypsin-like cleavage specificity, 
i.e., they preferentially cleave after aromatic amino acid residues. They are 
monomeric, and like tryptases, are stored fully active in the secretory granules 
in complex with serglycin PG (Braga et al., 2007; Henningsson et al., 2006; 
Abrink et al., 2004; Henningsson et al., 2002). Once released, they remain 
attached to the proteoglycan, which increases the activity of the enzyme and 
protects it from macromolecular inhibitors (Pejler & Sadler, 1999; Pejler & 
Berg, 1995). Chymases are divided into α- and β-chymases. Humans only 
express one α-chymase (Caughey et al., 1991), whereas mice express several 
different chymases. In mice, MMCs express the β-chymases mMCP-1 and -2, 
and CTMCs express the β-chymase mMCP-4 and the α-chymase mMCP-5 
(Huang et al., 1991; Reynolds et al., 1990). Phylogenetically, mMCP-5 is the 
closest homolog to the human chymase. However, mMCP-5 has elastase-like 
cleavage specificity and is therefore not functionally a chymase (Karlson et al., 
2003; Kunori et al., 2002). mMCP-4 on the other hand, has a similar cleavage 
specificity and tissue distribution as the human chymase and is therefore 
considered to be the functional homolog to the human chymase in mice 
(Andersson et al., 2008; Pejler et al., 2007).  
Studies have revealed that chymase is involved in processing of a wide 
array of proteins and peptides. Chymase can cleave angiotensin I yielding 
angiotensin II, a peptide that causes vasoconstriction (Urata et al., 1990; Reilly 
et al., 1982). Chymase has been shown to be involved in ECM remodeling via 
cleavage of the ECM component fibronectin (Tchougounova et al., 2003; 
Tchougounova et al., 2001; Vartio et al., 1981), as well as activation of MMPs 
and pro-collagenases (Tchougounova et al., 2005). A number of different 
cytokines have been shown to be substrates for chymase, including IL-1β 
(Mizutani et al., 1991), membrane-bound SCF (de Paulis et al., 1999), tumor 
necrosis factor (TNF) (Piliponsky et al., 2012) and IL-33 (Waern et al., 2013). 
To date, three chymase knockout mice have been generated: mMCP-1, 
mMCP-4 and mMCP-5. mMCP-1 is expressed in MMCs, primarily in the 
intestine and the mMCP-1 knockout mice have been shown to have delayed 
parasite expulsion in the intestine (Knight et al., 2000). The mMCP-5 
knockouts are, in addition to lackingmMCP-5, also lacking CPA, which makes 
it difficult to interpret data from these mice. Since mMCP-4 is functionally the 
closest homolog to human chymase, this knockout is perhaps the most 
interesting to study (Pejler et al., 2010). These mice have been used in many 
mouse models to evaluate the in vivo functions of mMCP-4. In a model of 
sepsis, CLP, mMCP-4 has been shown to enhance survival, in part by 
degrading and limiting the harmful effects of TNF (Piliponsky et al., 2012). 
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mMCP-4 has also been shown to have a detrimental role in models of arthritis 
(Magnusson et al., 2009), abdominal aortic aneurism (Sun et al., 2009) and 
bullous pemphigoid (Lin et al., 2011), yet a protective role in models of 
allergic airway inflammation (Waern et al., 2013; Waern et al., 2009). In 
addition, mMCP-4 has been shown to reduce the toxicity from a number of 
venoms, including from the gila monster and scorpion (Akahoshi et al., 2011).  
Carboxypeptidase A3 
CPA3 is a Zn-dependent metalloprotease that, similarly to the other mast cell 
proteases, is stored in an active form in complex with serglycin PG in the 
secretory granules. It is an exopeptidase that has a preference for cleaving C-
terminal aromatic and aliphatic residues (Pejler et al., 2007; Goldstein et al., 
1989). Both CPA3 and chymase have been suggested to remain in complex 
with serglycin PG after degranulation and, interestingly that cleavage of 
substrates by chymase can generate C-terminal ends that are substrates for 
CPA3 (Pejler et al., 2007). A CPA3 knockout mouse has been generated, but in 
analogy with the mMCP-5 knockout that also lacks CPA3, the CPA3 knockout 
lacks mMCP-5. To circumvent this problem, a CPA3inact mouse has been 
generated that retains the CPA3 protein but where the active site of CPA3 has 
been mutated, leading to enzymatically inactive CPA3. In these mice, the 
mMCP-5 protein is unaffected. CPA3 has been shown to be important for 
degrading certain toxic peptides, including endothelin-1 and certain snake 
venoms (Metz et al., 2006; Metsarinne et al., 2002).  
Other proteases expressed by mast cells 
In addition to the mast cell-specific proteases, mast cells also express many 
other proteases that are not exclusive to mast cells.  
Both human and murine mast cells have been shown to express granzyme 
B, which is primarily expressed by cytotoxic T cells (Pardo et al., 2007; Strik 
et al., 2007). Granzyme B derived from mast cells can cause cell death in 
susceptible adherent cells in vitro (Pardo et al., 2007). 
Cathepsin G is a serine protease mainly expressed by neutrophils but also 
expressed by mast cells. It has broad cleavage properties with both 
chymotrypic and tryptic activities, i.e., cleaving after both aromatic and basic 
amino acids (Polanowska et al., 1998; Schechter et al., 1990).  
MMPs are a family of Zn2+- and Ca2+-dependent metalloproteases, mainly 
involved in ECM remodeling. Human mast cells express MMP-1 (Di Girolamo 
& Wakefield, 2000) and MMP-9 (Kanbe et al., 1999c), and mouse mast cells 
express MMP-9 (Tanaka et al., 1999). 
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Mast cells also express ADAMTS-5, -6 and -9. The ADAMTSs are 
metalloproteases, which have been shown to possess aggrecanase activity 
(Garcia-Faroldi et al., 2013).  
 
2.5.2 Proteoglycans 
PGs are essential components of the mast cell secretory granules. PGs are 
glycoproteins that consist of a protein core with glycosaminoglycan (GAG) 
side chains. GAGs are polysaccharides that consist of repeating disaccharide 
units, which are highly anionic due to the presence of sulfate and carboxyl 
groups. There are several types of PGs, based on the protein core and the GAG 
chains. However, the dominant protein core expressed by mast cells is of 
serglycin type, while the side chains differ in different mast cell subtypes. In 
murine CTMCs, the PGs have heparin side chains (Kolset & Gallagher, 1990) 
and in MMCs, the side chains are of chondroitin sulfate type (Enerback et al., 
1985). In contrast, human mast cells contain both heparin and chondroitin 
sulfate, regardless of subtype (Pejler et al., 2009). Because of the highly 
negatively charged nature of serglycin PG it can interact with a number of 
positively charged molecules, including many of the mast cell proteases in the 
secretory granules. Indeed, serglycin knockout mast cells show defective 
storage of a number of different proteases including mMCP-4, mMCP-5, 
mMCP-6 and CPA3, as well as the biogenic amines histamine, serotonin and 
dopamine (Ronnberg et al., 2012a; Ringvall et al., 2008; Braga et al., 2007; 
Abrink et al., 2004).  
Upon mast cell degranulation, serglycin PG in complex with different 
compounds is released. Because of the change in pH outside the granules, 
some of the compounds will be released from serglycin, such as histamine, 
whereas others will remain attached, such as chymase and CPA3. Outside the 
granules, serglycin functions to protect the attached proteases from 
macromolecular inhibitor, as well as increasing the activity of chymase, and 
potentially attracting substrates to the proteases (Ronnberg et al., 2012b). 
2.5.3 Biogenic amines 
Mast cells are one of the main sources of histamine, although many other cell 
types produce it as well. Histamine has been widely studied and is associated 
with many physiological and pathological conditions. For example, histamine 
mediates inflammation, increases vascular permeability, acts on smooth muscle 
cells, stimulates gastric acid secretion and is a neurotransmitter in the central 
nervous system (Bachert, 2002). Histamine exerts its effects through histamine 
receptors H1, H2, H3 and H4 (Haaksma et al., 1990; Hill, 1990). In addition to 
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producing histamine, mast cells also express the H1, H2 and H4 receptors 
(Lippert et al., 2004).  
Mast cells also produce the biogenic amines serotonin and dopamine, both 
of which are mostly known as neurotransmitters (Kushnir-Sukhov et al., 2007; 
Freeman et al., 2001). 
2.5.4 Lipid mediators 
Activation of mast cells can initiate de novo synthesis of certain lipid 
mediators, prostaglandins and LTs, both members of the eicosanoid family. 
Mast cells have been shown to produce prostaglandin D2 (PGD2), LTB4 and 
LTC4 (Boyce, 2007). They are all derived from arachidonic acid, then released 
and actively transported from the cell (Funk, 2001). Once outside the cell, 
LTC4 is converted to LTD4 and subsequently LTE4 (Boyce, 2007). LTs 
mediate their biological effects via G-protein coupled receptors. They act as 
chemoattractants for neutrophils, macrophages, eosinophils, monocytes and 
mast cell progenitors. In addition, their physiological effects include 
bronchoconstriction, induction of cytokine production, vascular leakage, 
endothelial activation and tissue repair (Weller et al., 2005; Beller et al., 2004; 
Kanaoka & Boyce, 2004; Machida et al., 2004; Mellor et al., 2002; Peters-
Golden et al., 2002; Laitinen et al., 1993; Dahlen et al., 1980). Similarly to the 
LTs, PGD2 exerts its actions though G-protein coupled receptors. PGD2 is also 
a chemoattractant for a number of leukocytes (neutrophils, basophils and T 
helper 2 (TH2) cells) and it also mediates bronchoconstriction (Honda et al., 
2003; Fujitani et al., 2002; Johnston et al., 1992).  
2.5.5 Cytokines and chemokines 
Cytokines are molecules that are involved in cell signaling, with both systemic 
and local immunomodulatory effects. Chemokines are a family of cytokines 
named after their chemotactic properties. Cytokines and chemokines have a 
broad spectrum of functions, playing a major role in inflammation, infection, 
cell repair and growth. The list of cytokines and chemokines that mast cells can 
express is very long, including IL-1β, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, 
IL-13, IL-33, basic fibroblast growth factor-2, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), TNF-α, transforming growth factor 
(TGF)-β1, MCP-1 and RANTES (Ono et al., 2003; Lindstedt et al., 2001; 
Ishizuka et al., 1999; Kanbe et al., 1999a; Kanbe et al., 1999b; Kasahara et al., 
1998; Qu et al., 1998; Zhang et al., 1998; Gibbs et al., 1997; Okayama et al., 
1995; Razin et al., 1984). The list includes both classical pro-inflammatory 
cytokines, such as TNF-α and IL-1β, and cytokines that are associated with 
anti-inflammatory or immunomodulatory effects, such as IL-10 and TGF-β. 
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The majority of the secreted cytokines are newly synthesized upon mast cell 
activation. However, mast cells can also pre-store certain cytokines in their 
granules, which was initially shown for TNF-α (Walsh et al., 1991; Young et 
al., 1987).  
2.6 Mast cell-deficient mice 
2.6.1 Kit-dependent mast cell-deficient mice 
Most of the in vivo mast cell data is based on studies of mast cell-deficient Kit 
mutant mice. Kit is the tyrosine receptor for SCF, which is the main growth 
factor for mast cells in vivo, but SCF also has many other functions. Kit is 
expressed both inside and outside of the hematopoietic lineage, in cell types of 
diverse developmental origin. In the immune system, Kit is an important 
hematopoietic stem and progenitor cell marker. In most lineages Kit expression 
is lost with differentiation, the exception to this being mast cells, which 
mainatin a high Kit expression throughout their development. Kit also has 
many functions outside the immune system: it is important in germ cells, 
melanocytes (Besmer et al., 1993), intestinal pacemaker cells (Sergeant et al., 
2002), neuronal cells (Milenkovic et al., 2007) and in liver metabolism 
(Magnol et al., 2007). 
The Kit mutant mice exist with variable phenotypes, depending on naturally 
occurring alleles, the most relevant for mast cell studies being KitW, KitW-v and 
KitW-sh. The majority of the mast cell literature is based on the mutant KitW/W-v 
mouse. The Kitw protein cannot be expressed on the cell surface and the KitW-v 
protein has impaired kinase activity (Nocka et al., 1990). By breeding these 
two mice, mast cell-deficient KitW/W-v mice are produced. The KitW/W-v mice 
are severely affected by their Kit deficiency. They are sterile, have severe 
macrolytic anemia (Waskow et al., 2004), impaired T-cell development in the 
thymus (Waskow et al., 2002), have a shift in intraepithelial T cells in the gut 
in favor of T cell receptor (TCR) αβ+, instead of γδ+ cells (Puddington et al., 
1994), and they have reduced numbers of neutrophils (Zhou et al., 2007) and 
basophils (Feyerabend et al., 2011; Mancardi et al., 2011). KitW-sh mice have a 
large genomic inversion that affects the transcriptional regulatory elements 
upstream of the Kit gene (Berrozpe et al., 1999). This genomic rearrangement 
does not only affect the expression of Kit itself but can potentially lead to the 
dysregulation of 27 other genes (Nigrovic et al., 2008). The KitW-sh mice have 
been used more recently since they have fewer abnormalities than the KitW/W-v 
mice; they are fertile and have normal red blood cell numbers (Grimbaldeston 
et al., 2005). However, they do have neutrophilia, megakaryocytosis, 
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thrombocytosis and are associated with splenomegaly and histological 
aberrations of the spleen (Nigrovic et al., 2008). 
A way to prove that the phenotype seen in these mice is due to their mast 
cell deficiency has been to reconstitute them with mast cells derived either 
from bone marrow, bone marrow derived mast cells (BMMCs), or embryonic 
stem cells. The in vitro derived mast cells can be administered intravenously 
(i.v.), intraperitoneally (i.p.) or intradermally (i.d.) to create a so-called mast 
cell knock-in mouse (Figure 1) (Kawakami, 2009; Nakano et al., 1985). 
However, depending on the route of administration and the number of mast 
cells injected, the final numbers and anatomical distribution of the mast cells in 
reconstituted Kit mutant mice may not reflect the native mast cell population in 
wild type mice. For example, after i.v. injection of BMMCs, few or no mast 
cells are detectable in the trachea, whereas the number of mast cells in the 
periphery of the lungs is greater than in wild-type mice (Grimbaldeston et al., 
2005). However, depending on the administration, the mast cell population in 
certain anatomical sites is similar in number to wild-type, for example i.p. 
injection leads to similar numbers of mast cells in the peritoneum 
(Grimbaldeston et al., 2005). Studies have shown that, with time, the 
reconstituted mast cells will closely resemble the native population (Otsu et al., 
1987; Nakano et al., 1985). However, relatively few studies of this type have 
been done. Additionally, it is not possible to define every aspect of the mast 
cells in vivo, that is, it cannot be ruled out that adoptively transferred cells 
might have phenotypic differences to native mast cells. 
 22 
 
Figure 1. Mast cells derived from wild-type embryonic stem (ES) cells or bone marrow can be 
reconstituted into the mast cell-deficient mice (intravenously, i.v., intraperitoneally, i.p., or 
intradermally, i.d.). By comparing the 3 different groups of mice, wild-type, mast cell-deficient 
and reconstituted mast cell-deficient mice, conclusions can be made about the roles of mast cells 
in different in vivo models. 
 
2.6.2 Kit-independent mast cell-deficient mice 
Recently, several Kit-independent mast cell-deficient mice have been 
developed. A common approach has been to generate mice that express Cre-
recombinase under a promoter thought to be mast cell specific or at least mast 
cell associated. Cre-recombinase is a site-specific recombinase that catalyses a 
recombination event between two specific DNA fragments, loxP sites. DNA 
fragments found between two loxP sites are said to be “floxed”. The fate of this 
fragment, after Cre-mediated recombination, depends on the orientation of the 
loxP sites: if they are oriented in the same direction, the fragment will be 
excised, and if they are in opposite direction, it will be inverted (Brault et al., 
2007).  
Mcpt5-Cre; R-DTA mice 
These mice express Cre-recombinase under the control of the Mcpt5 (the gene 
for mMCP-5) promoter, a mast cell specific protease expressed in CTMCs. 
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They also have the gene for diphtheria toxin (DT) with a loxP floxed stop 
codon. Therefore, the DT is not expressed unless the floxed stop codon is 
removed by Cre-recombinase. When the stop codon is removed (i.e., in 
CTMCs), DT is expressed and the cell dies. These mice are basically devoid of 
mast cells in the peritoneum and only have 10% residual mast cells in the skin. 
Since mMCP-5 is a CTMC protease the MMCs are not affected. They have no 
other detected abnormalities (Dudeck et al., 2011). 
Cre-Master mice 
Cre-Master stands for Cre-mediated mast cell eradication. In these mice Cre-
recombinase is knocked-in under the control of the Cpa3 (the gene for CPA3) 
promoter, while deleting 28 nucleotides of the first exon of Cpa3. 
Unexpectedly, the Cpa3Cre/+ mice were virtually completely lacking mast cells. 
This depletion of mast cells appeared to be mediated by Cre-induced 
genotoxicity. When Cre-recombinase expression is very strong or long lasting, 
it can become promiscuous and toxic, independently of the presence of loxP 
sites. However, CPA3 is not only highly expressed in mast cells; it is also 
expressed in basophils and in some T-cell populations. Consistent with this, 
Cre activity can be seen in T cells in the Cre-Master mice and they have a 60 % 
reduction in spleen basophils (Feyerabend et al., 2011). 
Cpa3-Cre; Mcl-1fl/fl- “Hello Kitty” mice 
These mice express Cre-recombinase under the control of a promoter fragment 
of Cpa3 and the floxed gene of the anti-apoptotic factor, myeloid cell leukemia 
sequence 1 (Mcl-1). They have a reduction in numbers of mast cells (92-100%) 
but also show a reduction of basophils (58-78 %). These mice also showed a 
56% increase in splenic neutrophils and suffered macrolytic anemia (Lilla et 
al., 2011). 
 
2.6.3 Inducible depletion of mast cells 
In certain studies it can be interesting to induce a selective depletion of mast 
cells. One way to achieve this is by injection of DT into transgenic mice 
bearing the DT receptor (DTR) only on the particular cell type you want to 
deplete. Two different groups recently used this approach to deplete mast cells 
in adult mice. 
Mcpt5-Cre; iDTR mice 
Mcpt5-Cre mice were mated with iDTRfl/fl mice expressing a floxed simian 
DTR transgene in order to achieve Cre-dependent expression of DTR in mast 
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cells. Repeated injections of DT, once a week for 4 weeks, led to a complete 
ablation of mast cells in the peritoneal cavity and the skin, when assessed 1 
week after the last DT injection. The injections did not, however, affect 
MMCs, reflecting that Mcpt5 is not expressed in MMCs (Dudeck et al., 2011).  
Mas-TRECK mice 
Mas-TRECK stands for Mast cell-specific enhancer-mediated Toxin Receptor-
mediated Conditional cell Knock out. These mice express the human DTR 
gene under the control of an intronic enhancer (IE) element of the il-4 gene. 
This IE element has been shown to be mast cell specific. Repeated injections 
with DT lead to a complete loss of mast cells in the skin, peritoneal cavity, 
stomach and mesenteric windows, 3 days after the last DT treatment. Skin mast 
cells were also absent 12 days after DT treatment. However, DT treatment also 
transiently depleted blood basophils, while other major types of leukocytes 
were unaffected (Sawaguchi et al., 2012; Otsuka et al., 2011).  
A summary of the new Kit-independent mast cell-deficient mice can be 
seen in Table 2. Some of the mast cell related results from Kit-deficient mice 
have been confirmed in the new Kit-independent mice, including their roles in 
allergic airway hyperresponsiveness (Sawaguchi et al., 2012). However, there 
are also some conflicting data between the Kit-dependent and -independent 
mast cell-deficient mice, including the role of mast cell derived IL-10 in 
contact hypersensitivity (Dudeck et al., 2011) as well as the proposed role of 
mast cells in autoimmunity (Feyerabend et al., 2011). This has lead to a need to 
also re-evaluate other proposed roles of mast cells derived from experiments 
using the Kit-deficient mice (Reber et al., 2012; Rodewald & Feyerabend, 
2012). 
Table 2. A summary of Kit-independent mast cell-deficient mice. 
 Mcpt5-Cre  Mas-TRECK Cre-Master Cpa3-Cre 
Reference (Dudeck et al., 2011) (Sawaguchi et al., 
2012; Otsuka et 
al., 2011) 
(Feyerabend et 
al., 2011) 
(Lilla et al., 
2011) 
Construct Cre under the control of 
the Mcpt5 promoter 
Human DTR 
under the control 
of an intronic 
enhancer of the Il4 
gene 
Cre expression 
under the control 
of the Cpa3 
promoter 
Cre under the 
control of a Cpa3 
promoter 
fragment 
Additional 
loci 
R-DTA 
floxed 
Inducible 
DTR floxed 
  Mcl-1 floxed 
      
MC 
numbers 
Up to 97% of CTMCs; 
MMCs are not depleted 
Deficient for 
CTMCs and 
Deficient for 
CTMCs and 
92-100% 
including 
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MMCs MMCs CTMCs and 
MMCs 
Basophils Not affected  Depleted Reduced to 38% Reduced to 22-
42% 
Other 
alterations 
Not detected  Not detected Cre activity in T 
cells 
Macrolytic 
anemia, 
neutrophilia 
 
2.7 Mast cells in bacterial infections 
Mast cells are common at sites exposed to the external environment, such as 
the skin, the airways and the intestine. In these locations, they are well placed 
to function in host defense against invading pathogens.  
Many of the modes of mast cell activation discussed earlier can come into 
play during bacterial infections. Bacteria can activate mast cells both directly 
and indirectly. Direct detection of bacteria can be achieved through TLRs, 
NODs and CD48. Indirectly, mast cells can be activated by complement and 
through their FcRs, by the action of pathogen-specific antibodies. Bacterial 
superantigens can also activate mast cells through their FcRs, such as S. aureus 
derived protein A and Peptostreptococcus magnus derived protein L 
(Genovese et al., 2000). Mast cells can respond with widely differing cytokine 
and mediator profiles depending on the type of pathogen-associated signal they 
encounter. For example, rodent mast cells produce TNF-α, IL-1β, IL-6, GM-
CSF and several chemokines in response to LPS but they do not degranulate. 
In vivo, the mast cell response following LPS injection leads tot the recruitment 
of neutrophils (Supajatura et al., 2002; Leal-Berumen et al., 1994). On the 
other hand, PGN leads to production of a different range of cytokines, 
including IL-4, IL-5, IL-6 and GM-CSF, as well as induction of degranulation, 
which results in the development of local edema and increased vascular 
permeability in vivo (Supajatura et al., 2002). However, in another study, PGN, 
which binds TLR-2/6 heterodimers, was shown to induce proinflammatory 
cytokines and cysteinyl LTs with little or no degranulation. In contrast, tri-
palmitoylated lipopeptide, which binds to TLR-1/2 heterodimers, induced 
considerable degranulation and production of IL-1β and GM-CSF without the 
generation of LTs (Marshall et al., 2003; McCurdy et al., 2003). 
Mast cells can also produce compounds that have direct bactericidal 
activity, including several antimicrobial peptides, such as the human 
cathelicidin, LL37 or the mouse cathelicidin-related antimicrobial peptide 
(CRAMP). Mast cells deficient in CRAMP have a reduced ability to kill group 
A streptococci (Di Nardo et al., 2003). These compounds are both 
 26 
constitutively produced by mast cells as well as induced in response to various 
stimuli such as LPS (Di Nardo et al., 2003). 
2.7.1 Enhancement of effector cell recruitment 
Possibly the most important consequence of mast cell activation, in the context 
of bacterial infection, is the release of mediators that aid in the rapid 
recruitment of effector cells. Mast cells provide signals that can enhance each 
of the crucial stages of recruitment from the vasculature. IL-1, TNF, vascular 
endothelial growth factor, histamine and proteases can increase the 
permeability of the endothelial cell barrier as well as upregulate the expression 
and affinity of adhesion molecules. In addition, mast cells can produce 
chemoattractant compounds, such as C-X-C motif ligand (CXCL)8, CXCL11 
and LTs. Finally, mast cells also produce factors that can aid in the long-term 
survival of recruited cells, such as IL-1 and GM-CSF (Marshall, 2004). In vivo, 
the recruitment of neutrophils depends on mast cell-derived TNF, which 
increases adhesion molecule expression on the endothelium, and on the potent 
neutrophil chemoattractant LTB4 (Malaviya & Abraham, 2000). Mast cell-
derived tryptases have also been shown to be important for mobilization of 
neutrophils. When human tryptase is administered intratracheally, it induces 
more than a 100-fold increase in local neutrophil numbers and substantially 
decreases the susceptibility to airway infection by K. pneumoniae (Huang et 
al., 2001). In addition, mMCP-6 injected i.p. induces a substantial CXCL8-
independent recruitment of neutrophils that is dependent on the protease 
function (Huang et al., 1998). mMCP-6 knockout mice show early impaired 
neutrophil recruitment and decreased survival in response to intraperitoneal K. 
pneumoniae infection (Thakurdas et al., 2007). The mechanism by which 
tryptases induce neutrophil recruitment might involve the activation of PAR2, 
which is known to have an important role in leukocyte recruitment (Lindner et 
al., 2000; Vergnolle, 1999). In addition, mast cell chymase has been shown to 
recruit monocytes and neutrophils in vitro (Tani et al., 2000).  
2.7.2 Influence on adaptive immunity 
After stimulation, mast cells produce many factors that can influence the 
adaptive immune response. Mast cell-derived TNF induces upregulation of E-
selectin expression on the endothelium, promoting the influx of dendritic cells, 
which are subsequently increased in the draining lymph nodes (Shelburne et 
al., 2009). C-C motif ligand (CCL)20 from mast cells can also contributes to 
the recruitment of dendritic cells (Lin et al., 2003). Additionally, mast cells can 
activate Langerhans cells, a skin resident dendritic cell, which leads to 
increased numbers of Langerhans cells in the draining lymph nodes, in 
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response to PGN and gram-negative bacteria (Shelburne et al., 2009; Jawdat et 
al., 2006). Histamine has been suggested to promote antigen uptake and cross-
presentation (Amaral et al., 2007) as well as upregulate co-stimulatory 
molecules on dendritic cells required for T-cell activation (Caron et al., 2001).  
In addition to influencing cell trafficking to the lymph nodes, mast cell TNF 
is also crucial for retention of lymphocytes in the lymph nodes 24 hours after 
E. coli infection (McLachlan et al., 2003). This increases the probability of 
antigen-specific lymphocytes being present in the lymph nodes, and together 
with the ability of mast cells to mobilize dendritic cells, should increase the 
magnitude and specificity of the adaptive immune response. In a related study, 
wild-type mice were shown to have enhanced humoral immunity to E. coli 
compared to mast cell-deficient mice, including increased E. coli-specific 
antibodies and protection after passive immunization (Shelburne et al., 2009). 
There is also evidence that mast cells themselves can present antigen to T 
cells. Activated mast cells upregulate expression of MHC II and co-stimulatory 
molecules and they have been visualized physically interacting with T cells in 
vivo (Metcalfe et al., 1997). However, the in vivo the role of mast cells in 
antigen presentation during bacterial infections has not been studied. 
Conversely, T cells can modulate mast cells through the production of 
chemokines such as CCL3 (also known as MIP1α) and CCL2, as well as 
through physical contact between each other (Mekori & Metcalfe, 1999). This 
suggests that feedback regulation exists, where the adaptive immune system 
can modulate mast cell function during an ongoing infection.  
 
2.7.3 Mast cells in bacterial infections in vivo 
The first in vivo evidence that mast cells were important during bacterial 
infections came from two studies in KitW/W-v mice, where mast cells were 
shown to be protective in bacterial infection following either CLP (where the 
intestine of the mouse is punctured, releasing the cecal microflora into the 
peritoneum, and then ligated) or i.p. injection of live fimbriated E. coli and K. 
pneumoniae. Reconstitution of mast cells in the peritoneum restored the ability 
of the mice to survive the infections and efficiently clear the bacteria. Since 
then, mast cells have been shown to be protective in a number of different 
bacterial infections, including Mycoplasma pneumonia and Citrobacter 
rodentium (summarized in Table 3). However, mast cells and mast cell-derived 
TNF have also been reported to exacerbate mortality in severe CLP. This 
suggests that there is a delicate balance where the extent of the bacterial 
infection seems to determine the outcome of the mast cell response (Piliponsky 
et al., 2010). mMCP-4 has also been shown to be protective in CLP, at least in 
 28 
part, by degrading TNF and thereby limiting the detrimental effects of TNF 
(Piliponsky et al., 2012). 
Table 3. A summary of in vivo studies looking at the role of mast cells in bacterial infections. 
Bacteria Mice Comments Reference 
Cecal 
microflora 
KitW/W-v Decreased survival in KitW/W-v mice, a role 
for mast cell-derived TNF 
(Echtenacher et al., 
1996) 
 KitW/W-v Reconstitution of wild-type but not IL-12-
deficient mast cells corrects the defect 
(Nakano et al., 2007) 
 
 KitW-sh Mast cell-derived TNF can exacerbate 
mortality in severe CLP. 
(Piliponsky et al., 
2010) 
 KitW/W-v The protective role of the mast cells is 
mediated by TLR-4. 
(Supajatura et al., 
2001) 
 IL-15-/- IL-15 inhibits chymase activity and 
thereby constrains mast cell-dependent 
antibacterial defenses 
(Orinska et al., 2007) 
 Wild-type Repeated injections of SCF increases the 
numbers of mast cells and these mice 
show enhanced survival 
(Maurer et al., 1998) 
 mMCP-4-/- mMCP-4 promotes survival by degrading 
TNF and limiting the detrimental effects 
of TNF. 
(Piliponsky et al., 
2012) 
Escherichia 
coli 
KitW/W-v Decreased survival of mast cell-deficient 
mice, TNF important for the response. 
The FimH protein on the bacteria is 
important for the mast cell response. 
(Malaviya et al., 1996) 
 
 KitW/W-v Mast cell LTs have a role in neutrophil 
recruitment and bacterial clearance 
(Malaviya & Abraham, 
2000) 
 KitW/W-v A protective role of mast cells in urinary 
tract infection. 
(Malaviya et al., 2004) 
 KitW-sh Mast cell-derived TNF increases E-
selectin expression and dendritic cell 
recruitment to the infected skin. The 
serum antibody response is diminished 
and less protective in a urinary tract 
infection. 
(Shelburne et al., 2009) 
 KitW/W-v Mast cell-derived TNF induces 
hypertrophy of the draining lymph nodes. 
(McLachlan et al., 
2003) 
Klebsiella 
pneumoniae 
KitW/W-v Decreased survival of mast cell-deficient 
mice.  
(Malaviya et al., 1996) 
 IL-6-/. and 
KitW-sh 
Mast cell IL-6 improves survival by 
enhancing neutrophil killing. 
(Sutherland et al., 
2008) 
 mMCP-6-/- Impaired clearance of the bacteria and 
impaired early recruitment of neutrophils. 
(Thakurdas et al., 
2007) 
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Mycoplasma 
pneumonia 
KitW-sh Impaired clearance of the bacteria 
associated with increased lung pathology. 
(Xu et al., 2006) 
Citrobacter 
rodentium 
KitW/W-v Decreased survival, increased 
histopathology in the gut and increased 
bacterial spread. 
(Wei et al., 2005) 
Pseudomonas 
aeruginosa 
KitW/W-v Larger skin lesions in mast cell deficient-
mice and impaired neutrophil recruitment. 
Wild-type mice show pronounced mast 
cell degranulation. 
(Siebenhaar et al., 
2007) 
Listeria 
monocytogenes 
KitW/W-v 
and α2-
intergrin-/- 
Recruitment of neutrophils to the site of 
peritoneal infection dependent on mast 
cell α2β1-intergrins. 
(Edelson et al., 2004) 
Streptococcus 
pyogenes 
KitW/W-v Increased progressive tissue necrosis by 
the subcutaneous infection. 
(Matsui et al., 2011) 
Helicobacter 
Pylori 
KitW/W-v Mast cells are critical mediators of 
vaccine-induced Helicobacter clearance. 
(Velin et al., 2005) 
Francisella 
tularensis 
KitW/W-v 
and IL-4-/. 
Mast cells increase in the lung early (48 h) 
after infection and mast cell-deficient 
mice show decreased survival and 
bacterial clearance. In vitro studies 
showed mast cell inhibition of bacterial 
replication in macrophages by contact 
dependent events and secreted IL-4. 
(Ketavarapu et al., 
2008) 
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3 Present investigations 
3.1 Aims of the present studies 
The general aim has been to investigate the role of mast cells during bacterial 
infections. Specific attention was paid to a novel mast cell protease, granzyme 
D. 
 
 Investigate the global effect of live streptococci on mast cells in vitro. 
(paper I). 
 
 Investigate the expression and regulation of the novel mast cell protease 
granzyme D (paper II) 
 
 Investigate the global effect of live S. aureus on mast cells in vitro and 
study the role of mast cells in S. aureus infections in vivo (paper III) 
 
3.2 Results and Discussion 
3.2.1 Paper I: Infection of mast cells with live streptococci causes a toll-like 
receptor 2- and cell-cell contact-dependent cytokine and chemokine 
response.    
Mast cells have been implicated in immunity toward bacterial infections but 
the mechanisms by which mast cells contribute to the host defense are not fully 
understood. Several studies on the effects of bacterial components, such as LPS 
and PGN on mast cells have been done. However, very few studies have 
looked at the effect of live bacteria on mast cells. Therefore, the aim of the 
study (paper I) was to investigate the global effect of live streptococci on mast 
cells by using a number of approaches including unbiased strategies. 
 31 
We chose to use a gram-positive pathogen S. equi subspecies equi, a 
serological group C streptococcus that causes a severe upper respiratory tract 
infection in horses known as strangles (Timoney, 2004). S. equi can also infect 
mice. The bacteria were co-cultured with BMMCs, which were derived from 
mouse bone marrow by culturing them with WEHI-conditioned medium 
containing IL-3.  
To examine if co-culture with S. equi caused mast cell degranulation we 
measured histamine release from the cells. As a control, calcium ionophore 
was used, which caused a rapid and robust secretion of histamine. S. equi also 
caused histamine release but the response was much slower and lower 
compared to calcium ionophore. The cells were also examined with 
transmission electron microscopy and also here it was evident that no major 
degranulation had taken place. However, the cells had a dilated rough 
endoplasmic reticulum, indicative of elevated transcriptional activity. 
Furthermore, there were no signs of phagocytosis of bacteria by the mast cells.  
As an unbiased approach to look at cytokines produced by the mast cells in 
response to S. equi we used an antibody-based cytokine/chemokine array 
system. From this array it was evident that mast cells secrete multiple 
cytokine/chemokines when stimulated with S. equi, in particular IL-6, MCP-1, 
IL-13, TNF-α and IL-4. To examine whether this response was dependent on 
the bacteria being alive, BMMCs were stimulated with heat-inactivated S. equi. 
However, this only caused a minimal release of cytokines/chemokines as 
deduced by the array approach. To verify and quantify the cytokine/chemokine 
array results we used specific enzyme-linked immunosorbent assay (ELISA)s, 
where the secretion of high levels of IL-6, MCP-1, IL-13 and TNF-α in 
response to live S. equi were detected.  
Next, we investigated whether the mast cells and the bacteria needed to be 
in cell-cell contact for the mast cells to be activated. We did this by using 
transwell polystyrene plates, where the mast cells and bacteria were separated 
with a membrane with 0.4 µm pores. In this case only small amounts of 
cytokines (IL-6, MCP-1, IL-13 and TNF-α) were produced in response to S. 
equi indicating that the mast cells and bacteria needed to be in cell-cell contact 
for optimal activation. To further investigate this, we looked into which pattern 
recognition receptors were responsible for this activation. We chose to focus 
on TLR-2 and TLR-4, which have previously been shown to be expressed by 
mast cells. Using BMMCs derived from TLR-2-/- and TLR-4-/- mice, we could 
observed that the secretion of cytokines was markedly reduced in TLR-2-/- 
BMMCs compared to wild-type controls. There was also a reduction in TLR-4-
/- BMMCs. However, this reduction was not as pronounced as in the TLR-2-/- 
BMMCs. These results are consistent with the fact that S. equi is a gram-
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positive bacterium that contains PGN, which is recognized by TLR-2. 
However, the secretion of cytokines from the TLR-2-/- BMMCs were higher 
than in the non-infected controls, indicating that other receptors are also 
involved in the activation.  
To study the effects of S. equi co-culture on the BMMCs at the mRNA 
level, we used an Affymetrix gene chip microarray.  Using this approach, we 
could confirm the upregulation of the cytokines that were shown to be induced 
at the protein level (using the cytokine array). In addition, several other 
cytokines/chemokines were also upregulated at the mRNA level, including IL-
3, IL-2, CCL7 (MCP-3), CCL4 (MIP-1β), CCL1 (I-309), CXCL-2 (MIP-2) and 
CCL3 (MIP-1α). Using specific ELISAs, the upregulation of MCP-3 and MIP-
2 at the protein level was confirmed. A large number of other genes were also 
profoundly upregulated in response to S. equi; among these were many 
transcription factors, growth factors and genes implicated in signaling 
processes.  
 
Summary (paper I) 
 Mast cells are activated by S. equi and produce and release a number of 
different cytokines and chemokines, including TNF-α, MCP-1, IL-6, IL-13, 
MIP-2 and MCP-3. 
 The co-culture of mast cells with bacteria induces a slow release of 
histamine but no major degranulation takes place. 
 The mast cells do not phagocytose S. equi. 
 The bacteria need to be alive and in cell-cell contact to the mast cells for the 
activation to take place. 
 The activation is dependent on TLR-2, but also on other unknown 
receptors. 
 At the mRNA level, 155 genes were significantly (more then 4-fold) 
upregulated. Many of these genes were cytokines/chemokines, transcription 
factors, growth factors and genes implicated in signaling processes. 
      
3.2.2 Paper II: Granzyme D is a novel murine mast cell protease, highly 
induced by multiple pathways of mast cell activation. 
In paper I, we looked at which genes were upregulated in mast cells in 
response to S. equi, a gram-positive bacterium. One of the most highly 
upregulated genes was the one coding for granzyme D. Granzyme D is a 
protease that is mainly expressed in cytotoxic T cells, and there was no 
previous report indicating its expression by mast cells. Therefore, the aim of 
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this paper was to investigate the expression of granzyme D by mast cells more 
thoroughly. 
The expression of granzyme D in BMMCs was confirmed by real-time 
PCR, where the expression was correlated to mast cell maturation. In addition, 
the expression was upregulated in response to SCF, the main growth factor for 
mast cells. The expression of granzyme D was relatively low in resting mast 
cells but was highly inducible, occurring when activating mast cells in a 
number of different ways. The upregulation by the gram-positive bacteria S. 
equi was confirmed and granzyme D was also shown to be upregulated by the 
gram-negative bacteria E. coli, although to a much lower extent than to S. equi. 
Granzyme D was also directly upregulated by the bacterial cell wall 
components LPS and PGN. However, slightly contradicting results showed that 
granzyme D was upregulated to a lower extent by PGN, despite being the main 
component in gram-positive (i.e., S. equi) bacteria cell walls, than to LPS, the 
main component in gram-negative bacteria cell walls (i.e., E. coli). However, 
as shown in paper I, S. equi do not only activate the mast cells through TLR-2 
and PGN - other unknown receptors are also involved. Granzyme D was also 
shown to be upregulated through the classical way of activating mast cells, 
namely through IgE-receptor crosslinking and also directly through mobilizing 
calcium by using a calcium ionophore. The upregulation of granzyme D was 
shown to be dependent on a protein kinase C (PKC) (PKC inhibitor Gö6976, 
which inhibits PKC α/β1 and PKCD1), the transcription factor Nuclear factor 
of activated T-cells (NFAT) and to some extent the transcription factor nuclear 
factor-κβ (NF-κβ). 
Due to the difficulty of finding a specific granzyme D antibody that did not 
cross-react with the closely related granzyme B, which is abundantly expressed 
in mast cells, we developed a new antibody. Our new antibody did not cross-
react with granzyme B and we could see that granzyme D protein expression 
was linked to mast cell maturation, and it was released after calcium ionophore 
stimulation. Using immunohistology, we could also see that the granzyme D 
antibody stained mainly the perinuclear region in the mast cells. 
 
Summary (paper II) 
 Mast cells express granzyme D, which is associated with mast cell 
maturation. 
 Mast cell granzyme D is upregulated by live bacteria, LPS, PGN, SCF, IgE-
receptor crosslinking and calcium ionophore A23187. 
 The upregulation of granzyme D is dependent on a PKC and the 
transcription factor NFAT and to some extent the transcription factor NFκβ. 
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3.2.3 Paper III: Mast cells are activated by Staphylococcus aureus in vitro but 
do not influence the outcome of intraperioneal Staphylococcus aureus 
infection in vivo. 
In paper III we studied the mast cell response to S. aureus in vitro and also the 
contribution of the mast cell response to the course of the in vivo infection. 
Previous studies have shown that mast cells can degranulate in response to S. 
aureus and release TNF-α and IL-8. They can also exert anti-microbial activity 
against S. aureus by releasing extracellular traps and antimicrobial compounds 
(Abel et al., 2011). S. aureus evades the extracellular antimicrobial activity of 
mast cells by promoting its own uptake (Rocha-de-Souza et al., 2008). 
However, the global mast cell response to S. aureus has not been investigated. 
Therefore, we performed an Affymetrix microarray analysis of S. aureus- 
infected murine peritoneal-cell derived mast cells (PCMCs), to study how S. 
aureus affected the mast cell gene expression. The mast cells responded by 
significantly upregulating 52 genes, with a higher than 2 log2fold change. Of 
these genes, several were cytokines and chemokines, indicating that S. aureus 
induces a strong pro-inflammatory response in mast cells. The cytokine IL-3 
was the gene induced to the highest extent of all genes. Other 
cytokines/chemokines that were upregulated included: IL-13, CCL3, TNF-α, 
CCL7, IL-6 and Leukemia inhibitory factor (LIF). Analysis by ELISA 
confirmed the upregulation of IL-3, IL-13 and TNF-α at the protein level.  
Mast cells have been shown to be important in combating many different 
bacteria in vivo, as shown by assessment of the Kit-dependent mast cell-
deficient mice, KitW/W-v and KitW-sh (Abraham & St John, 2010). However, the 
importance of mast cells in S. aureus infection has not been investigated. 
Furthermore, the new Kit-independent mast cell-deficient mice have not been 
used in the context of bacterial infection. Therefore, we did i.p. infection with 
S. aureus in Mcpt5-Cre+ x R-DTA mice, with littermate Mcpt5-Cre- x R-DTA 
mice as mast cell-sufficient controls. We euthanized the mice after 4 hours as 
well as 3 days, and studied changes in weight, bacterial clearance and 
inflammatory cell influx in the peritoneum. In this infection model, the mast 
cells did not affect any of these parameters. Since we had seen that mast cells 
responded to S. aureus by releasing various cytokines in vitro we decided to 
look at the cytokine profile in the peritoneum. However, also here, we could 
not see any effect of the mast cell deficiency. There could be many reasons for 
the discrepancy between our results and the earlier published results showing 
that mast cells are important in bacterial infections. Many of the earlier 
published infection models are severe and have death as an end point; in 
contrast our infection is a quite mild one that the mice recover from. It is thus 
possible that mast cells do not have a big impact on mild infections. There are 
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also published results from the CLP model, where the extent of the infection 
determines whether mast cells promote or decrease survival (Piliponsky et al., 
2010). Another major difference is the use of different mouse strains. The Kit-
dependent mast cell-deficient mice have, in addition to lacking mast cells, 
many other abnormalities. A role of mast cells has therefore been proven by 
reconstituting the mast cell-deficient mice with mast cells. However, it is not 
certain that the reconstituted mast cells that are derived from BMMCs will 
have the same distribution and function as normal mast cells. Moreover, 
studies on the recently developed Kit-independent mast cell-deficient mice 
have provided some conflicting data in comparison with those based on the use 
of KitW/W-v and KitW-sh mice (Reber et al., 2012; Rodewald & Feyerabend, 
2012). This has led to the need to re-evaluate results based on the KitW/W-v and 
KitW-sh mice in the new Kit-independent mice, including the protective role in 
bacterial infections. Our data may thus indicate that mast cells might not play 
as big a role in bacterial infections as previously believed. However, to make 
more general conclusions about the roles of mast cells in bacterial infections, it 
will be imperative to perform more extensive studies in the novel Kit-
independent mast cell-deficient mice, using different bacterial strains and 
different experimental setups. 
 
Summary (paper III) 
 Mast cells upregulate many genes in response to live S. aureus in vitro. 
Many of these genes are cytokines/chemokines including IL-3, IL-13, 
CCL3, TNF-α and LIF. 
 Mast cells have no impact on in vivo i.p. S. aureus infection in respect to 
weight loss, bacterial clearance and inflammatory cell influx. 
 Mast cells do not contribute to the total cytokine profile in the peritoneum 
of i.p. S. aureus infected mice. 
 36 
4 Concluding remarks and future 
perspectives 
Mast cells are mostly known for their detrimental effects in allergy and asthma 
but they also have important functions in the immune response towards 
pathogens. Their location at sites that are exposed to the external environment, 
such as the skin, gut and the lungs, plus the fact that they are equipped with 
many receptors, which can recognize pathogens, makes them a good candidate 
for a “first line of defense” cell.  
Most of the evidence of how mast cells react to bacteria is based on in vitro 
studies involving responses to purified bacterial cell wall components, such as 
LPS and PGN. To investigate how mast cells react to live bacteria, we have 
done in vitro experiments where we co-cultured mast cells with S. equi or S. 
aureus. They reacted by producing many cytokines and chemokines. Despite 
both S. equi and S. aureus being gram-positive bacteria the response was quite 
different, with the mast cells reacting more strongly to S. equi. This difference 
could also be due to the use of different mast cells: BMMCs in the case of S. 
equi and PCMCs in the case of S. aureus. It would be interesting to investigate 
the response of the more mature PCMCs to S. equi, and deduce what is making 
the mast cells react stronger to S. equi. In addition, it would be interesting to 
see how cultured mast cells react to a spectrum of other bacterial strains in 
order to see if the mast cells have a specific response to certain types of 
bacteria.  
One of the genes that were upregulated in response to live S. equi was 
granzyme D, a protease that had not been shown to be expressed by mast cells 
before. Naturally, it is important to understand function of granzyme D. 
Generation of a granzyme D knockout mouse would greatly increase the 
possibilities to study this. The optimal tool to study the function of granzyme D 
in mast cells would be a mouse that has the granzyme D gene floxed with loxP 
sites. This mouse could be crossed with one that expresses Cre-recombinase in 
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mast cells, such as the Mcpt5-Cre, to generate a mouse that is lacking 
granzyme D only in mast cells.  
Mast cells have been shown to be important in combating many different 
bacteria in studies that used Kit-deficient mice. However, since Kit not only 
effects mast cells but also many other cell types within and outside the immune 
system, interpretation of data from these mice is not straight forward. 
Therefore, a new generation of Kit-independent mast cell-deficient mice has 
been generated. There are some reported discrepancies between results from 
the Kit-dependent and the Kit-independent mice. Therefore, it is important to 
re-evaluate the results obtained in Kit-dependent mast cell-deficient mice in the 
new generation of mast cell-deficient mice, including the roles of mast cells in 
bacterial infections. We have investigated the roles of mast cells in i.p. S. 
aureus infection in the Mcpt5-Cre+ x R-DTA mice, and found no impact of the 
mast cell-deficiency on weight loss, bacterial clearance and inflammatory cell 
influx. However, to make more general conclusions about the role of mast cells 
in bacterial infections, it is imperative to investigate these mice in other models 
of bacterial infection, for example via other routes of infection and other 
bacterial strains. Since mast cells in culture reacted stronger to S. equi than to 
S. aureus, it would be interesting to use this bacterial strain in the Mcpt5-Cre+ 
x R-DTA mice. It would also be interesting to investigate other aspects of the 
mast cells during a bacterial infection, such as their effects on the adaptive 
immune system. This could be done by looking at the recruitment of dendritic 
cells to the site of infection, the effects on the draining lymph nodes, the 
generation of bacterial-specific antibodies and the effect of mast cells in a 
secondary infection. 
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5 Populärvetenskaplig sammanfattning 
Varje dag träffar vår kropp på många organismer, såsom bakterier, virus och 
parasiter, som potentiellt kan infektera oss. Det är vårt immunförsvars uppgift 
att ta hand om dessa organismer så att de inte orsakar sjukdom. 
Immunförsvaret består av en rad olika celler, en av dessa celler är mastcellen. 
Mastceller innehåller en stor mängd sekretoriska vesiklar (granula) och vid 
aktivering frisätts innehållet i dessa granula till den närliggande miljön. Den 
mest kända granulakomponenten är histamin men även en rad cytokiner 
(signalmolekyler mellan celler), proteoglykaner (består av en proteinkärna med 
kolhydrater kopplade till sig) och proteaser (klipper sönder andra proteiner i 
kroppen) finns lagrade. Förutom att frisätta innehållet i dess granula kan 
aktiverade mastceller också nyproducera och frisätta olika substanser. Förutom 
att hjälpa till att försvara oss mot sjukdomsalstrande organismer är mastcellen 
också involverad i olika typer av sjukdomstillstånd, främst astma och allergier. 
Denna avhandling har fokuserat på hur mastcellerna reagerar och fungerar 
vid en bakteriell infektion. Tidigare studier har visat hur mastcellen reagerar på 
komponenter från bakteriens cellvägg men vi var intresserade av hur dem 
reagerar på levande bakterier. Vi har därför odlat mastceller tillsammans med 
de levande bakterierna Streptococcus equi (artikel I) och Staphylococcus 
aureus (artikel III). Vi kunde se att mastcellerna bland annat reagerade genom 
att producera och frisätta ett antal olika cytokiner. Cytokiner används i kroppen 
för att signalera mellan olika delar av immunförsvaret. Genom att frisätta 
cytokiner kan alltså mastcellen kommunicera till andra celler att vi är utsatta 
för ett bakterie angrepp. 
En annan molekyl som vi såg att mastceller producerade när de odlades 
tillsammans med bakterier var proteaset granzyme D (artikel II). Detta proteas 
har inte visats att det produceras av mastceller tidigare. Vi kunde också se att 
mastcellen producerade granzyme D i respons till andra stimuleringar än 
bakterier, bland annat aktivering via antikroppar.  
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Mastceller är beroende av en tillväxtfaktor som heter stamcellfaktor och 
dess receptor Kit för att kunna växa. Möss som är defekta i Kit har därför inga 
mastceller. Studier på Kit-defekta möss har visat att mastceller är viktiga vid 
bakterieinfektioner. Problemet är att Kit-defekta möss inte bara saknar 
mastceller, utan också har många andra problem, eftersom stamcellfaktor är en 
viktig tillväxtfaktor för många celler. Därför har det nyligen utvecklats nya 
möss som saknar mastceller men inte har några andra defekter. En av dessa 
möss, de så kallade Mcpt5-Cre+ x R-DTA-mössen, har vi använt för att utreda 
om mastcellen är viktig vid Staphylococcus aureus infektion i bukhålan. Vi 
kunde dock inte se någon skillnad på dessa möss och möss som har mastceller 
när vi tittade på viktminskning, bakteriell ”clearance” (hur bra de dödade 
bakterierna), rekrytering av andra immunceller och produktion av cytokiner. 
Men för att kunna dra mer generella slutsatser om vilken roll mastceller har vid 
bakterieinfektion måste det dock utföras försök med dessa nya möss och andra 
infektionsmodeller (andra bakteriestammar och andra infektionsställen).  
 
Slutsatser: 
 Mastceller producerar en rad olika cytokiner när de odlas tillsammans med 
levande bakterier (Streptococcus equi (artikel I) och Staphylococcus aureus 
(artikel III)). 
 Mastcellen innehåller proteaset granzyme D, och det produceras till högre 
grad när mastcellen aktiveras bland annat via bakterier och antikroppar 
(artikel II). 
 Mastcellen har ingen betydelse vid Staphylococcus aureus infektion i 
bukhålan i möss, vad det gäller viktminskning, bakteriell clearance, 
rekrytering av immunceller och produktion av cytokiner (artikel III). 
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